The study of atropine therapeutic effect on myopic progression in children

illustrative image

LitePharmTech Co., Ltd is recruiting patients for the clinical trial of STudy of Atropine Therapeutic Effect on Myopic Progression (STAMP).

This study is to evaluate the therapeutic effect and safety of LPTAT in children with myopia.

The primary objective is to evaluate the superiority of LPTAT to placebo in slowing myopia progression through the change of SE(Spherical Equivalent), which is measured by cycloplegic autorefraction after 12-month treatment.

The researchers plan that May 25, 2022 will be the study start date. The indicative completion of the clinical trial will be expected in December 31, 2023.

Among primary outcome measures are the Change in Spherical Equivalent over 12-month and Change in spherical equivalent measured by cycloplegic autorefraction at 12 months after administration of clinical trial drug compared to baseline.

The page dedicated to this clinical trial can be found here: https://ichgcp.net/clinical-trials-registry/NCT05528172.

Clinical Research News

Upcoming Clinical Trials

3